alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
III

★(Star Print)

103D CONGRESS

2D SESSION S. RES. 250

To refer S. 2409 entitled ‘‘A bill for the relief of D.W. Jacobson, Ronald

Karkala, and Paul Bjorgen of Grand Rapids, Minnesota.’’ to the chief

judge of the United States Court of Federal Claims for a report thereon.

IN THE SENATE OF THE UNITED STATES

AUGUST 19 (legislative day, AUGUST 18), 1994

Mr. DURENBERGER submitted the following resolution; which was referred to

the Committee on the Judiciary

RESOLUTION

To refer S. 2409 entitled ‘‘A bill for the relief of D.W.

Jacobson, Ronald Karkala, and Paul Bjorgen of Grand

Rapids, Minnesota.’’ to the chief judge of the United

States Court of Federal Claims for a report thereon.

1 Resolved, That the bill S. 2409 entitled ‘‘A bill for

2 the relief of D.W. Jacobson, Ronald Karkala, and Paul

3 Bjorgen of Grand Rapids, Minnesota.’’ now pending in the

4 Senate, together with all the accompanying papers, is re5 ferred to the chief judge of the United States Court of

6 Federal Claims. The chief judge shall proceed with the

7 same in accordance with the provisions of sections 1492

8 and 2509 of title 28, United States Code, and report
2

•SRES 250 IS1S

1 thereon to the Senate, at the earliest practicable date, giv2 ing such findings of fact and conclusions thereon as shall

3 be sufficient to inform the Congress of the nature and

4 character of the demand as a claim, legal or equitable,

5 against the United States or a gratuity and the amount,

6 if any, legally or equitably due to the claimants from the

7 United States.

Æ
### RESUMEN DIA**G SEROEPIDEMIOLOGICO 2008**

**MES 3 A** **BC EIT**  **B VIA**  **A ENERO**  **2135 112**  **471 FEBRERO**  **768 16**  **MA RZO**  **1936 70**  **57 AB**  **RIL 4928**  **275 310**  **MA YO**  **10818 387**  **72 JUNIO**  **9680 320**  **JULIO 7392**  **550 44**  **AG OST** **O 4400**  **183 45**  **SEPTIEMBRE 3070**  **245 92**  **OCT UBRE**  **4048 159**  **85 NOVIEMBRE**  

### 3696 **243 30**  **DICIEMBRE** 

### 2640 **120 37**  **TO TA** **L** 

### 55511 **2680 1243**
EXHIBIT 32.1

                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350
                            AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report of Community National
Bancorporation (the "Company") on Form 10-QSB for the three months ended
September 30, 2005 as filed with the Securities and Exchange Commission on
or about the date hereof (the "Report"), the undersigned, Theron G. Reed,
principal executive and financial officer of the Company, does hereby certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

     1.  The Report fully complies with the requirements of section 13(a) of
         the Securities Exchange Act of 1934; and

     2.  The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations
         of the Company.


/s/Theron G. Reed
------------------------------
Theron G. Reed
President and Chief Executive Officer
(principal executive and financial officer)

November 14, 2005
------------------------------
Date
Eighth Amendment to Change of Control Severance Plan



 Exhibit 10.20 
 EIGHTH AMENDMENT TO THE 
 AMGEN INC. 
 CHANGE OF CONTROL SEVERANCE PLAN 
 The Amgen Inc. Change of Control Severance
Plan (the “Plan”) is hereby amended, effective January 1, 2007, as follows: 
  

	1.	Section 1(M) of the Plan shall be amended and restated in its entirety as follows: 

 (M) “Group I Participants” shall mean those senior executive-level staff members of the Company, Amgen USA Inc., and Amgen Worldwide Services, Inc., Immunex Corporation, Immunex Manufacturing
Corporation, Immunex Rhode Island Corporation, and Amgen SF, LLC, Amgen Fremont Inc., and Amgen Mountain View Inc. whom the Administration Committee has designated as Group I Participants. At or before the occurrence of a Change of Control, the
Company shall notify the Group I Participants in writing of their status as Participants in the Plan. 
  

	2.	Section 1(N) of the Plan shall be amended and restated in its entirety as follows: 

 (N) “Group II Participants” shall mean those management-level staff members of the Company, Amgen USA Inc., and Amgen Worldwide Services, Inc., Immunex Corporation, Immunex Manufacturing
Corporation, Immunex Rhode Island Corporation, Amgen SF, LLC, Amgen Fremont Inc., and Amgen Mountain View Inc. at Job Level 8 or equivalent and above and who are not Group I Participants, as such group shall be constituted immediately prior to a
Change of Control. At or before the occurrence of a Change of Control, the Company shall notify the Group II Participants in writing of their status as Participants in the Plan. 
  

	3.	Section 1(O) of the Plan shall be amended and restated in its entirety as follows: 

 (O) “Group III Participants” shall mean those management-level staff members of the Company, Amgen USA Inc., and Amgen Worldwide Services, Inc., Immunex Corporation, Immunex Manufacturing
Corporation, Immunex Rhode Island Corporation, Amgen SF, LLC, Amgen Fremont Inc., and Amgen Mountain View Inc. at Job Level 7 or equivalent, as such group shall be constituted immediately prior to a Change of Control. At or before the occurrence of
a Change of Control, the Company shall notify the Group III Participants in writing of their status as Participants in the Plan. 
 To record
this Eighth Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 15th day of December 2006. 
  

			
	AMGEN INC.
		
	By:	 	 /s/ BRIAN MCNAMEE

	Title:	 	Senior Vice President, Human Resources
#### § 1.1504-2 [Reserved]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3080 Breath nitric oxide test system. ( a ) *Identification.* A breath nitric oxide test system is a device intended to measure fractional nitric oxide in human breath. Measurement of changes in fractional nitric oxide concentration in expired breath aids in evaluating an asthma patient's response to anti-inflammatory therapy, as an adjunct to established clinical and laboratory assessments of asthma. A breath nitric oxide test system combines chemiluminescence detection of nitric oxide with a pneumotachograph, display, and dedicated software.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance entitled “Class II Special Controls Guidance Document: Breath Nitric Oxide Test System.” See § 862.1(d) for the availability of this guidance document.
[68 FR 40127, July 7, 2003]
```

[Congressional Bills 103th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 272 Introduced in Senate (IS)]

103d CONGRESS
  2d Session
S. RES. 272

  Authorizing the taking of a photograph in the Chamber of the United 
                             States Senate.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

           September 28 (legislative day, September 12), 1994

    Mr. Mitchell (for himself and Mr. Dole) submitted the following 
             resolution; which was considered and agreed to

_______________________________________________________________________

                               RESOLUTION

 
  Authorizing the taking of a photograph in the Chamber of the United 
                             States Senate.

    Resolved, That paragraph 1 of Rule IV of the Rules for the 
Regulation of the Senate Wing of the United States Capitol (prohibiting 
the taking of pictures in the Senate Chamber) be temporarily suspended 
for the sole and specific purpose of permitting an official photograph 
to be taken of the United States Senate in actual session on a date and 
time to be announced by the Majority Leader after consultation with the 
Republican Leader.
    Sec. 2. The Sergeant at Arms of the Senate is authorized and 
directed to make the necessary arrangements therefor, which 
arrangements shall provide for a minimum of disruption to Senate 
proceedings.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE>               5
<LEGEND>
The Schedule contains summary financial information extracted
from the financial statements for Freedom Tax Credit Plus L.P.
and is qualified in its entirety by reference to such financial state-
ments
</LEGEND>
<CIK>                               0000854926
<NAME>  Independence Tax Credit Plus L.P.
<MULTIPLIER>                        1

<S>                                 <C>
<PERIOD-TYPE>                       3-MOS
<FISCAL-YEAR-END>                   MAR-31-2000
<PERIOD-START>                      APR-01-1999
<PERIOD-END>                        JUN-30-1999
<CASH>                              5,379,682
<SECURITIES>                        119,304
<RECEIVABLES>                       0
<ALLOWANCES>                        0
<INVENTORY>                         0
<CURRENT-ASSETS>                    1,053,794
<PP&E>                              142,812,577
<DEPRECIATION>                      40,768,479
<TOTAL-ASSETS>                      110,470,203
<CURRENT-LIABILITIES>               79,282,548
<BONDS>                             0
<PREFERRED-MANDATORY>               0
<PREFERRED>                         0
<COMMON>                            0
<OTHER-SE>                          31,187,655
<TOTAL-LIABILITY-AND-EQUITY>        110,470,203
<SALES>                             0
<TOTAL-REVENUES>                    3,495,360
<CGS>                               0
<TOTAL-COSTS>                       0
<OTHER-EXPENSES>                    3,541,218
<LOSS-PROVISION>                    0
<INTEREST-EXPENSE>                  1,212,778
<INCOME-PRETAX>                     (1,258,636)
<INCOME-TAX>                        0
<INCOME-CONTINUING>                 0
<DISCONTINUED>                      0
<EXTRAORDINARY>                     0
<CHANGES>                           0
<NET-INCOME>                        (1,258,636)
<EPS-BASIC>                       (16.90)
<EPS-DILUTED>                       0



</TABLE>
EXHIBIT
32








CERTIFICATION
PURSUANT TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Fonix Corporation on Form 10-Q for the
period ending March 31, 2008, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), I, Roger D. Dudley, Chief
Executive Officer and Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:





(1)
            The
      Report fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.











/s/ Roger D.
Dudley


Roger D.
Dudley


President,
Chief Executive Officer, and


Chief
Financial Officer


(Principal
Executive Officer, Principal Accounting Officer)





Dated May
20, 2008
Exhibit 10.28.3



Exhibit 10.28.3

 




THIRD AMENDMENT


TO THE


COVENTRY HEALTH CARE, INC.


SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN


WHEREAS, Coventry Health Care, Inc. (the “Company”) maintains the Coventry Health Care, Inc. Supplemental Executive Retirement Plan (the “Plan”); and


WHEREAS, pursuant to Section 9.1 of the Plan, the Company may amend the Plan at any time; and


WHEREAS, the Company wishes to amend the Plan, effective as provided below.


NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby amended as follows, effective as provided below:


1.            The name of the Plan is changed to “The Coventry Health Care, Inc. 401(k) Restoration and Deferred Compensation Plan,” effective as of December 1, 2006.


2.            Article IX of the Plan is amended, effective December 22, 2006, to read as follows:


“ARTICLE IX.


 


AMENDMENT, MERGER AND TERMINATION OF PLAN





	
             
 	
            9.1
 	
            Amendment of Plan
 





The Corporation, by action of its Chief Executive Officer, may at any time amend the Plan in whole or in part, provided, however, that no amendment shall be effective to decrease or restrict any Deferred Compensation Account maintained pursuant to any existing Deferred Compensation Agreement under the Plan.


 





	
             
 	
            9.2
 	
            Merger of Plan
 





The Corporation, by action of its Chief Executive Officer, may at any time merge the Plan and its related Trust with another non-qualified plan maintained by the Employer or any member of a controlled group of corporations as defined in Code Section 1563 or a member of an affiliated service group as defined under Code Section 414(m).


 





	
             
 	
            9.3
 	
            Termination of Plan
 





The Corporation, by action of the Compensation Committee of the Board, may at any time terminate the Plan with respect to new deferral elections, as to any Eligible Employee or in its entirety if, in the judgment of the Compensation Committee of the Board, the tax, accounting, or other effect of the continuance of the Plan, or any potential payment thereunder would not be in the best interest of the Employer.  If the Plan is terminated in its entirety or as to any Eligible Employee, each affected Participant shall be 100% vested in the value of his Deferred Compensation Account.  


 


NY:1399107v2


 








Upon such termination, each Participant will receive the value of his Deferred Compensation Account in the form of a lump-sum payment to be made no later than 120 days following the termination date.”


 





	
             
 	
            3.
 	
            Except as provided above, the Plan remains in full force and effect.
 





The Company has caused this amendment to the Plan to be executed by its duly authorized officer this 24th day of January, 2007.





	
             
 	
            COVENTRY HEALTH CARE, INC.
 





 





	
             
 	
            By:    /s/ Dale B. Wolf  
 









	
             
 	
            Title:   Chief Executive Officer  
 





 


 





	
            NY:1399107v2
 	
            - 2 -
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

November 29, 2006 Clifford W. Taylor,

 Chief Justice 

Michael F. Cavanagh 

Elizabeth A. Weaver 132127 

Marilyn Kelly 

Maura D. Corrigan 

Robert P. Young, Jr. 

Stephen J. Markman, PEOPLE OF THE STATE OF MICHIGAN, Justices 

Plaintiff-Appellee, 

v SC: 132127 

 COA: 270706 
 Wayne CC: 05-002666

JOSEPH WALTER PEACOCK,

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the August 4, 2006 order 

of the Court of Appeals is considered, and it is DENIED, because we are not persuaded 

that the question presented should be reviewed by this Court. 

d1120 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

November 29, 2006 

 Clerk
§ 884.1720 Gynecologic laparoscope and accessories. ( a ) *Identification.* A gynecologic laparoscope is a device used to permit direct viewing of the organs within the peritoneum by a telescopic system introduced through the abdominal wall. It is used to perform diagnostic and surgical procedures on the female genital organs. This generic type of device may include: Trocar and cannula, instruments used through an operating channel, scope preheater, light source and cables, and component parts.
( b ) *Classification.* ( 1 ) Class II (performance standards).
( 2 ) Class I for gynecologic laparoscope accessories that are not part of a specialized instrument or device delivery system, do not have adapters, connector channels, or do not have portals for electrosurgical, lasers, or other power sources. Such gynecologic laparosope accessory instruments include: the lens cleaning brush, biopsy brush, clip applier (without clips), applicator, cannula (without trocar or valves), ligature carrier/needle holder, clamp/hemostat/grasper, curette, instrument guide, ligature passing and knotting instrument, suture needle (without suture), retractor, mechanical (noninflatable), snare, stylet, forceps, dissector, mechanical (noninflatable), scissors, and suction/irrigation probe. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 884.9.
[45 FR 12684, Feb. 26, 1980, as amended at 61 FR 1124, Jan. 16, 1996; 66 FR 38808, July 25, 2001]
§ 1.541-1 Imposition of tax. ( a ) Section 541 imposes a graduated tax upon corporations classified as personal holding companies under section 542. This tax, if applicable, is in addition to the tax imposed upon corporations generally under section 11. Unless specifically excepted under section 542(c) the tax applies to domestic and foreign corporations and, to the extent provided by section 542(b), to an affiliated group of corporations filing a consolidated return. Corporations classified as personal holding companies are exempt brom the accumulated earnings tax imposed under section 531 but are not exempt from other income taxes imposed upon corporations, generally, under any other provisions of the Code. Unlike the accumulated earnings tax imposed under section 531, the personal holding company tax imposed by section 541 applies to all personal holding companies as defined in section 542, whether or not they were formed or availed of to avoid income tax upon shareholders. See section 6501(f) and § 301.6501(f)-1 of this chapter (Regulations on Procedure and Administration) with respect to the period of limitation on assessment of personal holding company tax upon failure to file a schedule of personal holding company income.
( b ) A foreign corporation, whether resident or nonresident, which is classified as a personal holding company is subject to the tax imposed under section 541 with respect to its income from sources within the United States, even though such income is not fixed or determinable annual or periodical income specified in section 881. A foreign corporation is not classified as a personal holding company subject to tax under section 541 if it is a foreign personal holding company as defined in section 552 or if it meets the requirements of the exception provided in section 542(c)(10).
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3880 Tympanostomy tube. ( a ) *Identification.* A tympanostomy tube is a device that is intended to be implanted for ventilation or drainage of the middle ear. The device is inserted through the tympanic membrane to permit a free exchange of air between the outer ear and middle ear. A type of tympanostomy tube known as the malleous clip tube attaches to the malleous to provide middle ear ventilation. The device is made of materials such as polytetrafluoroethylene, polyethylene, silicon elastomer, or porous polyethylene.
( b ) *Classification.* Class II.
NOTE: This disposition is nonprecedential.

United States Court of Appeals 

for the Federal Circuit ______________________ 

THE TURFGRASS GROUP, INC. AND 

UNIVERSITY OF GEORGIA RESEARCH

FOUNDATION, INC.,

Plaintiffs-Appellants,

v.

CAROLINA FRESH FARMS, INC., CAROLINA 

FRESH FARMS, L.L.C., formerly known as Carolina 

Fresh Farms, Inc., AND JOHN A. FOGLE, SR.,

Defendants-Appellees.

______________________ 

2014-1017

______________________ 

Appeal from the United States District Court for the 

District of South Carolina in No. 5:10-CV-00849, Judge J. 

Michelle Childs.

______________________ 

JUDGMENT

______________________ 

DAMON C. WLODARCZYK, Riley Pope & Laney, LLC, of 

Columbia, South Carolina, argued for plaintiffsappellants. Of counsel on the brief was DUFF NOLAN, 

Nolan Law Group, PLLC, of Stuttgart, Arizona.
 

ROBERT F. GOINGS, Goings Law Firm, LLC, of Columbia, South Carolina, argued for defendants-appellees. Of 

counsel on the brief was CHRISTIAN E. BOESL, Collins & 

Lacy, P.C., of Columbia, South Carolina.

______________________ 

THIS CAUSE having been heard and considered, it is

ORDERED and ADJUDGED: 

 PER CURIAM (PROST, Chief Judge, NEWMAN and 

TARANTO, Circuit Judges).

AFFIRMED. See Fed. Cir. R. 36.

 ENTERED BY ORDER OF THE COURT

 December 11, 2014 /s/ Daniel E. O’Toole

 Date Daniel E. O’Toole 

 Clerk of Court
IN THE SUPREME COURT OF THE STATE OF MONTANA

JOHN MILLER,

Petitioner,

v .

OP 20-0404

MONTANA SIXTH JUDICIAL DISTRICT

COURT, HONORABLE BRENDA

GILBERT, PRESIDING,

Respondent.

AUG 2 5 2020

Bowen Greenwood

Clerk of Supreme Court

rlf Montana

ORDER

Through counsel, John Miller filed a verified Petition for a Writ of Certiorari

(Review) on August 13, 2020, pursuant to 3-1-523, MCA. In the Petition, Miller states he

has requested a transcript of the hearing in the Sixth Judicial District Court, Hon. Brenda

Gilbert, presiding, which imposed attorney's fees and costs upon a finding of contempt.

Miller also states that this Court should order the transcript of the June 18, 2020 contempt

hearing to be transmitted to this Court.

A transcript of this proceeding would facilitate review of this matter. Section 27-

25-202, MCA. As of August 24, 2020, no transcript has been filed with this Court.

Therefore,

IT IS ORDERED that the Court Reporter for the Sixth Judicial District Court, Park

County, PREPARE and FILE a copy of the transcript for the June 18, 2020 hearing in

Cause No. DP-18-42, In re the Estate offack Bates, within 10 days of this Order. Counsel

for Petitioner John Miller shall arrange for payment for this transcript, if it has not already

occurred.

The Clerk of the Supreme Court shall provide a copy of this Order to Sandra

Hogstad, Court Reporter, Sixth Judicial District; to the Honorable Brenda Gilbert, Sixth

08/25/2020

Case Number: OP 20-0404
Judicial District Court; to Molly Bradberry, Clerk of District Court, Park County, under

Cause No. DP-18-42; and to counsel of record.

DATED this ay of August, 2020.

Chief Justice

2
#### § 1.1368-4 Effective date and transition rule.

Except for §§ 1.1368-1(e)(2), 1.1368-2(a)(5), and 1.1368-3 *Example 2, Example 4,* and *Example 5,* §§ 1.1368-1, 1.1368-2, and 1.1368-3 apply to taxable years of the corporation beginning on or after January 1, 1994. Section 1.1368-1(e)(2), § 1.1368-2(a)(5), and § 1.1368-3 *Example 2, Example 4,* and *Example 5* apply only to taxable years of the corporation beginning on or after August 18, 1998. For taxable years beginning before January 1, 1994, and taxable years beginning on or after January 1, 1997, and before August 18, 1998, the treatment of distributions by an S corporation to its shareholders must be determined in a reasonable manner, taking into account the statute and legislative history. Except with regard to the deemed dividend rule under § 1.1368-1(f)(3), § 1.1368-1(e)(2), § 1.1368-2(a)(5), and § 1.1368-3 *Example 2, Example 4,* and *Example 5,* return positions consistent with §§ 1.1368-1, 1.1368-2, and 1.1368-3 are reasonable for taxable years beginning before January 1, 1994. Return positions consistent with §§ 1.1368-1(e)(2), 1.1368-2(a)(5), and 1.1368-3 *Example 2, Example 4,* and *Example 5* are reasonable for taxable years beginning on or after January 1, 1997, and before August 18, 1998.

[T.D. 8852, 64 FR 71651, Dec. 22, 1999]